Abstract: Objective:To compare the therapeutic and adverse effects of concurrent raltitrexed plus oxaliplatin and radiotherapy with those of PF synchronous radiotherapy in the treatment of advanced esophageal cancer. Methods:A total of 84pathologically con-firmed patients with advanced esophageal carcinoma were randomly distributed to the concurrent raltitrexed plus oxaliplatin and ra -diotherapy group (experimental group,n=40) and to the PF synchronous radiotherapy group (control group, n=44). All patients were treated with3DCRT at a total dose of 60Gy/30f. The chemotherapy in the experimental group consists of raltitrexed at 2. 5 mg/m2, d1, plus oxaliplatin at130 mg/m2, d2. The chemotherapy of the control group consists of DDP at 25mg/m2, Dd 1- 3, plus 5-FU 500 mg/m2,d 1- 5. Two cycles of concurrent chemotherapy were administered during radiotherapy on d1 and d29. The comparison results were used to estimate the therapeutic and adverse effects of the two groups. Results:The rerponse rate, complete response, and one-year overall survival rate of the experimental group were higher than those of the control group ( 87. 50% vs . 79. 54%,P=0. 3293), (32. 50% vs . 18. 18%,P=0. 13), and ( 82. 50% vs . 79. 50%,P=0. 701 ), but the difference was not statistically significant. The incidence rates of nau -sea and vomiting, appetite degression, leucopenia, radiation-induced esophagitis, and cardiotoxicity were significantly lower ( P<0. 05) in the experimental group than in the control group. Other adverse effects of the two groups were similar (P>0. 05). Conclusion: Simi -lar to PF chemotherapy and radiotherapy, the concurrent raltitrexed plus oxaliplatin and radiotherapy achieved a similar short- term therapeutic effect but lower adverse effects on patients with esophageal cancer.